On May 25, 2023 Carina Biotech (Carina), a cell therapy immuno-oncology company, reported that the management team will participate in the three upcoming conferences as follows (Press release, Carina Biotech, MAY 25, 2023, View Source [SID1234632051]):
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
9th Annual Immuno-Oncology Innovation Forum will be held in person in Chicago on June 2. Deborah Rathjen, Carina’s Chief Executive Officer, is scheduled to participate in the Competing in the Cell & Gene Therapy Space panel on June 2 at 11:20 am CT. The Carina team plans to host meetings and present on Friday, June 2 at 2:35 pm CT.
2023 ASCO (Free ASCO Whitepaper) Annual Meeting will be held in person in Chicago and online from June 2-6. The Carina team will be sharing a poster presentation showcasing its Phase 1/2a clinical trial of its LGR5-targeted CAR-T cell therapy candidate CNA3103 in patients with metastatic colorectal cancer (mCRC).
Poster Details
Title: A phase 1/2a, multicenter, open-label study of CNA3103 (LGR5-targeted, autologous CAR-T cells) in patients with metastatic colorectal cancer (mCRC)
Lead Author: José Iglesias, MD, Carina’s Chief Medical Officer
Session Type/Title: Poster Session – Gastrointestinal Cancer—Colorectal and Anal
Session Date and Time: Monday June 5, 2023 from 8:00 AM CDT – 11:00 AM CDT
Published Abstract Number: TPS3632
2023 BIO International Convention will be held in-person in Boston from June 5-8. The Carina team will host meetings at the event.
(Download pdf here)
About CNA3103
Carina’s proprietary CNA3103 CAR-T cell targets LGR5, a cancer stem cell marker that is highly expressed on advanced colorectal cancer and some other cancers. In colorectal cancer patients, LGR5 expression has been correlated with poor prognosis. Cancer stem cells are a small sub-population of cells within a tumor with the ability to self-renew, differentiate into the many cell types of a tumor, initiate new tumors, and resist chemotherapy and radiotherapy (leading to relapses). By targeting cancer stem cells, it is hoped that this therapy will reduce the tumor’s ability to generate new cancer cells, resulting in durable tumor suppression and preventing the relapses that are very common in patients with colorectal cancer. Carina’s pre-clinical studies of CNA3103 have shown promising results with complete tumor regression and no tumor recurrence following a single administration. CNA3103 has also demonstrated impressive tumor access and prolonged survival, enabling rejection of new tumors.